🇺🇸 GILD — Gilead Sciences, Inc.

Salud Compra
← Volver

Precio actual

166,89 USD

Máx. histórico

174,48

2 días

Split 2:1 del 28/01/2013

Caída desde máximo

-4,35%

Rango 52 semanas

116,88 – 176,58

Variación hoy

-0,41%

Cierre anterior

167,57

Rango de hoy

164,00 – 169,06

Volumen hoy

5.695.172

Peor caída histórica

-70,83%

27/01/1992 → 06/06/1994

Recuperado en 431 días

Volatilidad anualizada ⓘ

46,20%

Información
Nombre completo
Gilead Sciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
17.000
PER ⓘ
—
Dividend yield
1,96% (puede no estar actualizado)
Precio objetivo analistas
172,50 USD (puede no estar actualizado)
Primera cotización
22/01/1992
Precio actualizado
hace 1 día
Sobre la empresa

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Dividendos repartidos Total últimos 12 meses: 3,2500 USD · Yield: 1,95%
Fecha de pago Importe por participación
15/09/2026 0,8200 USD
15/06/2026 0,8200 USD
13/03/2026 0,8200 USD
15/12/2025 0,7900 USD
15/09/2025 0,7900 USD
13/06/2025 0,7900 USD
14/03/2025 0,7900 USD
13/12/2024 0,7700 USD
13/09/2024 0,7700 USD
14/06/2024 0,7700 USD
14/03/2024 0,7700 USD
14/12/2023 0,7500 USD
14/09/2023 0,7500 USD
14/06/2023 0,7500 USD
14/03/2023 0,7500 USD
Splits Registrados en el histórico de precios
Fecha Ratio
28/01/2013 2:1
25/06/2007 2:1
07/09/2004 2:1
08/03/2002 2:1
22/02/2001 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/05/2013 56,60 56,64 54,20 54,96 -2,48% 4,31% 15.554.100
15/05/2013 56,34 57,10 55,09 56,36 +0,20% 3,57% 16.779.100
14/05/2013 54,49 56,27 54,40 56,25 +3,27% 3,43% 16.929.400
13/05/2013 53,12 55,09 52,93 54,47 +3,01% 4,07% 14.485.400
10/05/2013 52,77 53,15 52,19 52,88 +0,17% 1,82% 12.752.600
09/05/2013 52,58 53,22 52,25 52,79 +0,78% 1,84% 9.815.900
08/05/2013 53,13 53,41 51,99 52,38 -1,41% 2,67% 12.612.500
07/05/2013 54,37 54,60 52,82 53,13 -2,39% 3,27% 14.096.100
06/05/2013 55,18 55,70 54,12 54,43 -1,31% 2,86% 13.330.700
03/05/2013 54,55 56,35 54,52 55,15 +5,69% 3,35% 17.089.300
02/05/2013 52,75 53,21 51,95 52,18 +4,07% 2,39% 16.602.700
01/05/2013 50,45 50,65 49,86 50,14 -0,99% 1,57% 9.679.100
30/04/2013 50,75 50,89 49,43 50,64 -0,88% 2,88% 13.550.600
29/04/2013 51,36 51,63 50,77 51,09 -0,56% 1,67% 10.806.000
26/04/2013 51,49 52,25 51,29 51,38 -0,10% 1,86% 9.678.600
25/04/2013 51,30 51,84 50,91 51,43 +1,70% 1,81% 10.862.700
24/04/2013 53,18 53,52 50,43 50,57 -5,18% 5,81% 18.388.700
23/04/2013 54,40 55,16 52,58 53,33 -1,33% 4,74% 13.828.200
22/04/2013 54,12 54,24 53,29 54,05 +1,66% 1,76% 15.188.600
19/04/2013 50,66 53,98 50,66 53,17 +4,54% 6,55% 20.436.500
18/04/2013 51,88 52,06 50,53 50,86 -2,08% 2,95% 9.391.500
17/04/2013 51,70 52,20 50,73 51,94 -0,13% 2,84% 12.453.000
16/04/2013 51,27 52,05 51,06 52,01 +2,62% 1,93% 13.561.900
15/04/2013 52,25 52,36 50,62 50,68 -2,41% 3,33% 13.210.200
12/04/2013 51,66 52,43 51,39 51,93 +0,54% 2,01% 10.697.000
11/04/2013 50,20 51,97 50,18 51,65 +3,86% 3,57% 15.567.100
10/04/2013 48,52 49,85 48,50 49,73 +2,96% 2,78% 10.084.900
09/04/2013 48,09 48,81 47,99 48,30 +2,33% 1,71% 13.126.300
08/04/2013 47,25 47,61 46,85 47,20 -0,36% 1,61% 9.538.000
05/04/2013 46,90 47,45 46,53 47,37 -0,78% 1,96% 10.958.000